A Phase 3, Randomized, Multicenter, Open Label Study, Comparing CC 92480, Bortezomib and Dexamethasone (480Vd), with Pomalidomide, Bortezomib and Dexamethasone PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM).
Principal Investigator: Pekka Anttila
HUS Helsinki University Hospital, Comprehensive Cancer Center
